文献速递浆细胞疾病

卡非佐米在复发和/或难治性多发性骨髓瘤临床试验中的心血管安全性特征分析

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
PubMed 文献 · Blood Adv · 2018-01-01

该分析汇总了超过2000例暴露于卡非佐米的复发和/或难治性多发性骨髓瘤(RRMM)患者的1-3期试验数据,描述心血管不良事件(AE)发生率;并比较3期研究中卡非佐米组超过1000例患者与对照组的个体心血管安全性数据以评估获益-风险特征。汇总显示≥3级心血管AE包括高血压(5.9%)、呼吸困难(4.5%)和心脏衰竭(4.4%);卡非佐米组任何级别和≥3级心脏衰竭、呼吸困难及高血压发生率数值上增加,但因这些心脏事件停药或死亡频率低且与对照组相当;盲法心脏亚研究连续超声心动图显示两组均无心脏功能障碍客观证据,且卡非佐米对心脏复极无显著影响。

要点

  • 汇总卡非佐米试验中≥3级心血管AE:高血压5.9%、呼吸困难4.5%、心脏衰竭4.4%。
  • 卡非佐米组任何级别和≥3级心脏衰竭、呼吸困难及高血压发生率数值上增加。
  • 因这些心脏事件停药或死亡频率低,且卡非佐米组与对照组相当。

核心结论

  • 包括OS获益在内的结果表明,在大多数患者中卡非佐米治疗在减少进展或死亡方面的获益超过发生心脏衰竭或高血压的风险。
  • 推荐对老年患者和有潜在危险因素的患者进行适当的卡非佐米给药和危险因素管理。

研究设计与样本

  • 分析纳入1-3期临床试验,超过2000例暴露于卡非佐米的RRMM患者,以描述心血管不良事件(AE)发生率。
  • 此外,比较3期研究中卡非佐米组超过1000例患者与对照组的个体心血管安全性数据,以评估卡非佐米的获益-风险特征。

主要发现

  • 汇总卡非佐米试验数据,≥3级心血管AE包括高血压(5.9%)、呼吸困难(4.5%)和心脏衰竭(4.4%)。
  • 卡非佐米组任何级别和≥3级心脏衰竭、呼吸困难及高血压发生率数值上增加,但因这些心脏事件停药或死亡频率低且与对照组相当。
  • 盲法心脏亚研究连续超声心动图显示卡非佐米组和对照组均无心脏功能障碍的客观证据。
  • 卡非佐米对心脏复极无显著影响。

关键数值与推荐

  • 汇总卡非佐米试验中≥3级心血管AE发生率:高血压5.9%、呼吸困难4.5%、心脏衰竭4.4%。

临床怎么用

  • 推荐对老年患者和有潜在危险因素的患者进行适当的卡非佐米给药和危险因素管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or refractory multiple myeloma (RRMM). It has significantly improved outcomes, including overall survival (OS), and shown superiority vs standard treatment with lenalidomide plus dexamethasone and bortezomib plus dexamethasone. The incidence rate of cardiovascular (CV) events with carfilzomib treatment has varied across trials. This analysis evaluated phase 1-3 trials with >2000 RRMM patients exposed to carfilzomib to describe the incidence of CV adverse events (AEs). In addition, the individual CV safety data of >1000 patients enrolled in the carfilzomib arm of phase 3 studies were compared with the control arms to assess the benefit-risk profile of carfilzomib. Pooling data across carfilzomib trials, the CV AEs (grade ≥3) noted included hypertension (5.9%), dyspnea (4.5%), and cardiac failure (4.4%). Although patients receiving carfilzomib had a numeric increase in the rates of any-grade and grade ≥3 cardiac failure, dyspnea, and hypertension, the frequency of discontinuation or death due to these cardiac events was low and comparable between the carfilzomib and control arms. Serial echocardiography in a blinded cardiac substudy showed no objective evidence of cardiac dysfunction in the carfilzomib and control arms. Moreover, carfilzomib had no significant effect on cardiac repolarization. Our results, including the OS benefit, showed that the benefit of carfilzomib treatment in terms of reducing progression or death outweighed the risk for developing cardiac failure or hypertension in most patients. Appropriate carfilzomib administration and risk factor management are recommended for elderly patients and patients with underlying risk factors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chari A, Stewart AK, Russell SD, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018. PMID: 29991494. doi:10.1182/bloodadvances.2017015545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。